
By: **Senators Hollinger, Britt, Brochin, Conway, Currie, Exum, Forehand,
Frosh, Garagiola, Gladden, Grosfeld, Jones, Kasemeyer, Kelley, Kramer,
Lawlah, McFadden, Middleton, Pinsky, Ruben, and Teitelbaum**

Introduced and read first time: January 18, 2006

Assigned to: Education, Health, and Environmental Affairs and Budget and Taxation

A BILL ENTITLED

1 AN ACT concerning

2 **Maryland Stem Cell Research Act of 2006**

3 FOR the purpose of requiring certain persons to conduct certain research in a certain
4 manner; establishing the Maryland Stem Cell Research Fund; providing for the
5 purpose of the Fund; specifying that the Fund is a special, nonlapsing fund;
6 specifying that the State Treasurer shall hold the Fund separately and that the
7 Comptroller shall account for the Fund; specifying that certain proceeds shall be
8 invested and reinvested in a certain manner; specifying that certain earnings
9 shall be paid into the Fund; providing for the composition of the Fund; requiring
10 the Governor to include a certain appropriation in the annual budget bill;
11 requiring the Department of Health and Mental Hygiene to administer the
12 Fund; providing that money in the Fund may only be used for certain purposes;
13 requiring the Secretary of Health and Mental Hygiene to adopt certain
14 regulations; establishing the Maryland Scientific Peer Review Committee;
15 requiring the Committee to establish certain procedures, ensure that these
16 procedures are based on certain guidelines, develop and implement a certain
17 ranking and rating system, and make certain recommendations; providing for
18 the membership of the Committee; authorizing the Committee to invite certain
19 experts and certain consultants to certain meetings; requiring the Committee to
20 select a certain chair; providing for the filling of certain vacancies; requiring the
21 members of the Committee to make certain disclosures to the State Commission
22 on Ethics; requiring the Committee to meet at certain times in certain places;
23 requiring the Department to provide staff for the Committee; establishing the
24 Stem Cell Research Commission in the Department; providing for the
25 membership of the Commission; requiring the Governor to designate the chair of
26 the Commission; requiring the Department to provide staff for the Commission;
27 providing for the terms of certain members of the Commission; requiring the
28 members of the Commission to make certain disclosures to the State
29 Commission on Ethics; requiring the Commission to carry out certain functions
30 and duties; requiring the Commission to meet at certain times; providing for
31 certain contingencies; requiring a grantee to submit a certain approval;
32 prohibiting the Department from disbursing certain money under certain
33 circumstances; requiring certain reports; requiring certain health care

1 practitioners to provide certain individuals with certain information; requiring
2 certain individuals to provide certain consent to certain donations; providing
3 that certain provisions of law may not be construed to prohibit the creation of
4 certain stem cell lines to be used for certain purposes; prohibiting the purchase,
5 sale, transfer, or obtaining of human embryos for valuable consideration;
6 prohibiting the encouragement of the production of human embryos for certain
7 research; prohibiting human cloning; providing for certain penalties; defining
8 certain terms; providing for the staggering of certain terms; and generally
9 relating to State-funded stem cell research.

10 BY adding to

11 Article - Health - General

12 Section 20-1101 through 20-1112, inclusive, to be under the new subtitle

13 "Subtitle 11. Stem Cell Research"

14 Annotated Code of Maryland

15 (2005 Replacement Volume and 2005 Supplement)

16 Preamble

17 WHEREAS, An estimated 128,000,000 Americans suffer from the crippling
18 physical, economic, and psychological burdens of chronic, degenerative, and acute
19 diseases, including Alzheimer's disease, heart disease, diabetes, Parkinson's disease,
20 spinal cord injuries, macular degeneration, ALS, multiple sclerosis, and cancer; and

21 WHEREAS, The costs of treatment and lost productivity of chronic,
22 degenerative, and acute diseases in the United States constitute hundreds of billions
23 of dollars every year, and estimates of the economic costs of these diseases do not
24 account for the extreme human loss and suffering associated with these conditions;
25 and

26 WHEREAS, Stem cell research offers immense promise for developing new
27 medical therapies and a better understanding of these debilitating diseases and could
28 lead to unprecedented treatments and potential cures for Alzheimer's disease, heart
29 disease, diabetes, Parkinson's disease, cancer, and other diseases; and

30 WHEREAS, Approximately half of Maryland's families have a family member
31 who has or will suffer from a serious, often critical or terminal, medical condition that
32 could potentially be treated or cured with medical therapies derived from stem cell
33 research; and

34 WHEREAS, Maryland's current health care system may not be able to meet the
35 needs of these individuals in the future unless medical care can focus on early
36 diagnosis, cure, and prevention rather than palliation of late-stage effects of the
37 disease; and

38 WHEREAS, The United States and the State of Maryland have historically
39 fostered open scientific inquiry and technological innovation, and this environment,

1 coupled with the commitment of public and private resources, has made the United
2 States the preeminent world leader in biomedicine and biotechnology; and

3 WHEREAS, Maryland ranks as the fourth-largest sector for biotechnology
4 companies in the nation; and

5 WHEREAS, The biotechnology industry is a key component of the State's
6 economy that provides employment in over 300 companies, many of which engage in
7 some form of stem cell research; and

8 WHEREAS, The University of Maryland, Baltimore and The Johns Hopkins
9 University are involved in stem cell research, with projects representing a combined
10 total of approximately \$10,000,000 in public and private funding; and

11 WHEREAS, The State's favorable research climate would be significantly
12 diminished by limitations imposed on stem cell research; and

13 WHEREAS, Stem cell research, including the use of embryonic stem cells for
14 medical research, raises significant ethical and policy concerns that must be carefully
15 considered; and

16 WHEREAS, Public policy on stem cell research must balance ethical and
17 medical considerations and must be based on an understanding of the science
18 associated with stem cell research while grounded on a thorough consideration of the
19 ethical concerns; and

20 WHEREAS, Stem cell research must be carefully crafted to ensure that
21 researchers have the tools necessary to fulfill the promise of stem cell research; now,
22 therefore,

23 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
24 MARYLAND, That the Laws of Maryland read as follows:

25 **Article - Health - General**

26 **SUBTITLE 11. STEM CELL RESEARCH.**

27 20-1101.

28 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
29 INDICATED.

30 (B) "COMMISSION" MEANS THE STEM CELL RESEARCH COMMISSION IN THE
31 DEPARTMENT.

32 (C) "COMMITTEE" MEANS THE MARYLAND SCIENTIFIC PEER REVIEW
33 COMMITTEE.

34 (D) "EMBRYO" MEANS THE STAGE BETWEEN THE OVUM AND THE FETUS IN
35 PRENATAL DEVELOPMENT.

1 (E) "FUND" MEANS THE MARYLAND STEM CELL RESEARCH FUND.

2 (F) "HUMAN CLONING" MEANS THE REPLICATION OF A HUMAN BEING
3 THROUGH THE PRODUCTION OF A PRECISE GENETIC COPY OF HUMAN DNA OR ANY
4 OTHER HUMAN MOLECULE, CELL, OR TISSUE, IN ORDER TO CREATE A NEW HUMAN
5 BEING.

6 (G) "INSTITUTIONAL REVIEW BOARD" HAS THE MEANING STATED IN THE
7 FEDERAL REGULATIONS ON THE PROTECTION OF HUMAN SUBJECTS.

8 (H) "STATE-FUNDED STEM CELL RESEARCH" MEANS STEM CELL RESEARCH
9 CONDUCTED USING DONATED UNUSED HUMAN EMBRYOS WHICH WERE CREATED
10 FOR INDIVIDUALS BEING TREATED FOR INFERTILITY AND FOR WHICH A GRANT
11 FROM THE FUND IS SOUGHT OR AWARDED.

12 (I) "STEM CELL" MEANS A CELL THAT HAS THE ABILITY TO:

13 (1) DIVIDE;

14 (2) GIVE RISE TO SPECIALIZED CELLS; AND

15 (3) GIVE RISE TO NEW STEM CELLS WITH IDENTICAL POTENTIAL.

16 (J) (1) "VALUABLE CONSIDERATION" MEANS FINANCIAL GAIN OR
17 ADVANTAGE.

18 (2) "VALUABLE CONSIDERATION" DOES NOT INCLUDE REASONABLE
19 PAYMENT FOR THE REMOVAL, PROCESSING, DISPOSAL, PRESERVATION, QUALITY
20 CONTROL, STORAGE, TRANSPLANTATION, OR GRAFTING OF EMBRYONIC OR
21 CADAVERIC FETAL TISSUE.

22 20-1102.

23 A PERSON WHO CONDUCTS STATE-FUNDED STEM CELL RESEARCH SHALL
24 CONDUCT THE RESEARCH IN A MANNER THAT CONSIDERS THE ETHICAL AND
25 MEDICAL IMPLICATIONS OF THE RESEARCH.

26 20-1103.

27 (A) THERE IS A MARYLAND STEM CELL RESEARCH FUND.

28 (B) THE PURPOSE OF THE FUND IS TO PROMOTE STATE-FUNDED STEM CELL
29 RESEARCH AND CURES THROUGH GRANTS AND LOANS TO PUBLIC AND PRIVATE
30 ENTITIES IN THE STATE.

31 (C) THE FUND IS A SPECIAL, NONLAPSING FUND THAT IS NOT SUBJECT TO §
32 7-302 OF THE STATE FINANCE AND PROCUREMENT ARTICLE.

33 (D) THE STATE TREASURER SHALL HOLD THE FUND AND THE COMPTROLLER
34 SHALL ACCOUNT FOR THE FUND.

1 (E) THE PROCEEDS OF THE FUND SHALL BE INVESTED AND REINVESTED IN
2 THE SAME MANNER AS OTHER STATE FUNDS.

3 (F) ANY INVESTMENT EARNINGS SHALL BE PAID INTO THE FUND.

4 (G) THE FUND CONSISTS OF:

5 (1) AN APPROPRIATION EQUAL TO AT LEAST \$25,000,000 AS PROVIDED IN
6 THE STATE BUDGET; AND

7 (2) ANY OTHER MONEY FROM ANY OTHER SOURCE ACCEPTED FOR THE
8 BENEFIT OF THE FUND.

9 (H) BEGINNING IN FISCAL YEAR 2008 AND EACH FISCAL YEAR THEREAFTER,
10 THE GOVERNOR SHALL INCLUDE IN THE ANNUAL BUDGET BILL AN APPROPRIATION
11 EQUAL TO AT LEAST \$25,000,000 TO THE FUND.

12 (I) THE DEPARTMENT SHALL ADMINISTER THE FUND.

13 (J) MONEY IN THE FUND MAY ONLY BE EXPENDED TO:

14 (1) AWARD GRANTS AND LOANS FOR STATE-FUNDED STEM CELL
15 RESEARCH;

16 (2) AWARD GRANTS AND LOANS FOR FACILITIES, CAPITAL LEASES, AND
17 CAPITAL EQUIPMENT WHERE STATE-FUNDED STEM CELL RESEARCH IS
18 CONDUCTED; AND

19 (3) PAY THE COSTS NECESSARY TO ADMINISTER THE FUND.

20 (K) EXPENDITURES FROM THE FUND MAY ONLY BE MADE IN ACCORDANCE
21 WITH AN APPROPRIATION APPROVED BY THE GENERAL ASSEMBLY IN THE ANNUAL
22 STATE BUDGET OR BY AN APPROVED BUDGET AMENDMENT.

23 (L) THE SECRETARY, IN CONSULTATION WITH THE COMMISSION, SHALL
24 ADOPT REGULATIONS TO CARRY OUT THE PROVISIONS OF THIS SECTION,
25 INCLUDING:

26 (1) CRITERIA, STANDARDS, AND REQUIREMENTS FOR FUNDING
27 APPLICATIONS AND THE AWARD OF GRANTS AND LOANS FROM THE FUND;

28 (2) PROCEDURES FOR MAKING THE DISBURSEMENT OF A GRANT
29 CONTINGENT ON OBTAINMENT OF THE APPROVAL OF AN INSTITUTIONAL REVIEW
30 BOARD; AND

31 (3) STANDARDS FOR THE OVERSIGHT OF USE OF AWARDS.

32 20-1104.

33 (A) THERE IS A MARYLAND SCIENTIFIC PEER REVIEW COMMITTEE.

1 (B) THE COMMITTEE SHALL:

2 (1) ESTABLISH PROCEDURES FOR THE REVIEW OF RESEARCH
3 PROPOSALS FOR STATE-FUNDED STEM CELL RESEARCH;

4 (2) ENSURE THAT THE PROCEDURES ESTABLISHED UNDER ITEM (1) OF
5 THIS SUBSECTION ARE BASED ON THE GUIDELINES OF THE FEDERAL NATIONAL
6 INSTITUTES OF HEALTH'S CENTER FOR SCIENTIFIC REVIEW;

7 (3) DEVELOP AND IMPLEMENT A RANKING AND RATING SYSTEM
8 THROUGH WHICH AN OBJECTIVE ASSESSMENT MAY BE MADE OF RESEARCH
9 PROPOSALS REVIEWED UNDER ITEM (1) OF THIS SUBSECTION; AND

10 (4) MAKE RECOMMENDATIONS TO THE COMMISSION, BASED ON THE
11 RANKINGS AND RATINGS AWARDED TO RESEARCH PROPOSALS UNDER ITEM (3) OF
12 THIS SUBSECTION, FOR THE AWARD AND DISBURSEMENT OF GRANTS UNDER THE
13 FUND.

14 (C) (1) THE COMMITTEE SHALL CONSIST OF THE FOLLOWING MEMBERS
15 SELECTED FROM THE SCIENTIFIC COMMUNITY:

16 (I) TWO SHALL BE SELECTED BY THE SECRETARY;

17 (II) TWO SHALL BE SELECTED BY THE SECRETARY OF BUSINESS
18 AND ECONOMIC DEVELOPMENT;

19 (III) TWO SHALL BE SELECTED BY THE JOHNS HOPKINS
20 UNIVERSITY;

21 (IV) TWO SHALL BE SELECTED BY THE UNIVERSITY SYSTEM OF
22 MARYLAND; AND

23 (V) TWO SHALL BE SELECTED BY THE MARYLAND BIOSCIENCE
24 ALLIANCE.

25 (2) THE MEMBERS OF THE COMMITTEE SELECTED UNDER PARAGRAPH
26 (1) OF THIS SUBSECTION MAY BE FROM OUT OF STATE.

27 (3) THE COMMITTEE MAY INVITE EXPERTS AND CONSULTANTS TO
28 ATTEND MEETINGS OF THE COMMITTEE.

29 (D) THE COMMITTEE SHALL SELECT A CHAIR FROM AMONG ITS MEMBERS.

30 (E) A VACANCY ON THE COMMITTEE SHALL BE FILLED BY THE PERSON
31 UNDER SUBSECTION (C)(1) OF THIS SECTION WHO HAD SELECTED THE FORMER
32 MEMBER OF THE COMMITTEE.

33 (F) EACH MEMBER OF THE COMMITTEE SHALL DISCLOSE TO THE STATE
34 COMMISSION ON ETHICS WHETHER THE MEMBER IS EMPLOYED BY OR HAS A
35 FINANCIAL INTEREST IN AN ENTITY THAT MAY APPLY TO CONDUCT STATE-FUNDED
36 STEM CELL RESEARCH.

1 (G) THE COMMITTEE SHALL MEET AT LEAST TWICE EACH YEAR, AT THE
2 TIMES AND PLACES THAT IT DETERMINES.

3 (H) THE DEPARTMENT SHALL PROVIDE STAFF FOR THE COMMITTEE.
4 20-1105.

5 (A) THERE IS A STEM CELL RESEARCH COMMISSION IN THE DEPARTMENT.

6 (B) THE COMMISSION CONSISTS OF THE FOLLOWING MEMBERS:

7 (1) THE SECRETARY OR THE SECRETARY'S DESIGNEE;

8 (2) THE ATTORNEY GENERAL OR THE ATTORNEY GENERAL'S DESIGNEE;

9 (3) THE SECRETARY OF BUSINESS AND ECONOMIC DEVELOPMENT OR
10 THE SECRETARY'S DESIGNEE;

11 (4) THE STATE TREASURER OR THE TREASURER'S DESIGNEE;

12 (5) THE COMPTROLLER OR THE COMPTROLLER'S DESIGNEE; AND

13 (6) THE FOLLOWING MEMBERS APPOINTED BY THE GOVERNOR:

14 (I) TWO WITH EXPERTISE IN THE FIELD OF BIOMEDICAL ETHICS;

15 (II) ONE WITH EXPERTISE IN THE FIELD OF BIOMEDICAL ETHICS
16 AS IT RELATES TO RELIGION;

17 (III) ONE WHO WORKS AS A SCIENTIST AND ENGAGES IN STEM CELL
18 RESEARCH FOR THE UNIVERSITY SYSTEM OF MARYLAND;

19 (IV) ONE WHO WORKS AS A SCIENTIST AND ENGAGES IN STEM CELL
20 RESEARCH FOR THE JOHNS HOPKINS UNIVERSITY;

21 (V) ONE FROM THE MARYLAND BIOSCIENCE ALLIANCE; AND

22 (VI) TWO CONSUMER MEMBERS.

23 (C) THE GOVERNOR SHALL DESIGNATE THE CHAIR OF THE COMMISSION.

24 (D) THE DEPARTMENT SHALL PROVIDE STAFF FOR THE COMMISSION.

25 (E) (1) THE TERM OF AN APPOINTED MEMBER IS 4 YEARS.

26 (2) THE TERMS OF THE APPOINTED MEMBERS ARE STAGGERED AS
27 REQUIRED BY THE TERMS PROVIDED FOR MEMBERS ON OCTOBER 1, 2006.

28 (3) AT THE END OF A TERM, AN APPOINTED MEMBER CONTINUES TO
29 SERVE UNTIL A SUCCESSOR IS APPOINTED AND QUALIFIES.

1 (4) AN APPOINTED MEMBER MAY NOT SERVE MORE THAN TWO
2 CONSECUTIVE FULL TERMS.

3 (5) AN APPOINTED MEMBER WHO IS APPOINTED AFTER A TERM HAS
4 BEGUN SERVES ONLY FOR THE REST OF THE TERM AND UNTIL A SUCCESSOR IS
5 APPOINTED AND QUALIFIES.

6 (F) EACH MEMBER OF THE COMMISSION SHALL DISCLOSE TO THE STATE
7 COMMISSION ON ETHICS WHETHER THE MEMBER IS EMPLOYED BY OR HAS A
8 FINANCIAL INTEREST IN AN ENTITY THAT MAY APPLY TO CONDUCT STATE-FUNDED
9 STEM CELL RESEARCH.

10 20-1106.

11 (A) THE COMMISSION SHALL:

12 (1) ADOPT REGULATIONS THAT ENSURE THAT STEM CELL RESEARCH
13 FINANCED BY THE FUND COMPLIES WITH STATE LAW;

14 (2) RECOMMEND TO THE SECRETARY:

15 (I) CRITERIA, STANDARDS, AND REQUIREMENTS FOR
16 CONSIDERATION OF FUNDING APPLICATIONS BASED ON THE RANKINGS AND
17 RATINGS OF THE COMMITTEE; AND

18 (II) STANDARDS FOR THE OVERSIGHT OF USE OF AWARDS;

19 (3) REVIEW GRANT AND LOAN APPLICATIONS BASED ON CRITERIA AND
20 STANDARDS ADOPTED BY THE SECRETARY;

21 (4) MAKE RECOMMENDATIONS CONSISTENT WITH THE CRITERIA AND
22 STANDARDS ADOPTED BY THE SECRETARY AND BASED SOLELY ON THE RANKINGS
23 AND RATINGS OF THE COMMITTEE REGARDING THE AWARD OF GRANTS AND LOANS
24 FROM THE FUND;

25 (5) NOTIFY THE SECRETARY REGARDING THE SUBMISSION BY A
26 GRANTEE, OR FAILURE OF A GRANTEE, TO SUBMIT INSTITUTIONAL REVIEW BOARD
27 APPROVAL FOR A GRANT AWARDED UNDER THIS SUBTITLE; AND

28 (6) CONDUCT PROGRESS OVERSIGHT REVIEWS OF GRANTEES.

29 (B) THE COMMISSION SHALL MEET AT LEAST TWICE A YEAR.

30 20-1107.

31 (A) A GRANT AWARDED UNDER THIS SUBTITLE SHALL BE CONTINGENT ON:

32 (1) THE SUBMISSION BY A GRANTEE TO THE COMMISSION OF APPROVAL
33 FROM AN INSTITUTIONAL REVIEW BOARD; AND

1 (2) ENTRANCE INTO A MEMORANDUM OF UNDERSTANDING BETWEEN
2 THE GRANTEE AND THE DEPARTMENT THAT:

3 (I) ESTABLISHES THE SCOPE OF THE STATE'S OWNERSHIP OR
4 OTHER FINANCIAL INTEREST IN THE COMMERCIALIZATION AND OTHER BENEFITS
5 OF THE RESULTS, PRODUCTS, INVENTIONS, AND DISCOVERIES OF STATE-FUNDED
6 STEM CELL RESEARCH; AND

7 (II) TO THE EXTENT CONSISTENT WITH FEDERAL AND STATE LAW,
8 REFLECTS THE INTELLECTUAL PROPERTY POLICIES OF THE INSTITUTION.

9 (B) A GRANTEE SHALL SUBMIT THE APPROVAL REQUIRED UNDER
10 SUBSECTION (A)(1) OF THIS SECTION WITHIN 6 MONTHS OF THE AWARD OF THE
11 GRANT.

12 (C) THE DEPARTMENT MAY NOT DISBURSE GRANT MONEY TO A GRANTEE
13 UNTIL:

14 (1) THE APPROVAL REQUIRED UNDER THIS SECTION HAS BEEN
15 OBTAINED; AND

16 (2) THE MEMORANDUM OF UNDERSTANDING REQUIRED UNDER
17 SUBSECTION (A)(2) OF THIS SECTION HAS BEEN OBTAINED.

18 20-1108.

19 THE DEPARTMENT AND THE COMMISSION SHALL REPORT TO THE GOVERNOR
20 AND, IN ACCORDANCE WITH § 2-1246 OF THE STATE GOVERNMENT ARTICLE, TO THE
21 GENERAL ASSEMBLY ON OR BEFORE JANUARY 1 OF EACH YEAR ON THE PROGRESS
22 OF STATE-FUNDED STEM CELL RESEARCH CONDUCTED IN ACCORDANCE WITH THIS
23 SUBTITLE.

24 20-1109.

25 (A) A HEALTH CARE PRACTITIONER LICENSED UNDER THE HEALTH
26 OCCUPATIONS ARTICLE WHO TREATS INDIVIDUALS FOR INFERTILITY SHALL:

27 (1) PROVIDE INDIVIDUALS WITH INFORMATION SUFFICIENT TO ENABLE
28 THEM TO MAKE AN INFORMED AND VOLUNTARY CHOICE REGARDING THE
29 DISPOSITION OF HUMAN EMBRYOS; AND

30 (2) PRESENT TO INDIVIDUALS THE OPTION OF:

31 (I) STORING OR DISCARDING UNUSED HUMAN EMBRYOS;

32 (II) DONATING UNUSED HUMAN EMBRYOS FOR CLINICAL
33 PURPOSES IN THE TREATMENT OF INFERTILITY;

34 (III) DONATING UNUSED HUMAN EMBRYOS FOR RESEARCH
35 PURPOSES; AND

1 (IV) DONATING UNUSED HUMAN EMBRYOS FOR EMBRYO ADOPTION
2 PURPOSES.

3 (B) AN INDIVIDUAL WHO DONATES UNUSED HUMAN EMBRYOS FOR
4 RESEARCH PURPOSES UNDER SUBSECTION (A)(2) OF THIS SECTION SHALL PROVIDE
5 THE HEALTH CARE PRACTITIONER WITH WRITTEN CONSENT FOR THE DONATION.

6 20-1110.

7 NOTHING IN THIS SUBTITLE SHALL BE CONSTRUED TO PROHIBIT THE
8 CREATION OF STEM CELL LINES TO BE USED FOR THERAPEUTIC RESEARCH
9 PURPOSES.

10 20-1111.

11 (A) A PERSON MAY NOT PURCHASE, SELL, TRANSFER, OR OBTAIN HUMAN
12 EMBRYOS FOR VALUABLE CONSIDERATION UNDER THIS SUBTITLE.

13 (B) A PERSON MAY NOT GIVE VALUABLE CONSIDERATION TO ANOTHER
14 PERSON TO ENCOURAGE THE PRODUCTION OF HUMAN EMBRYOS FOR THE SOLE
15 PURPOSE OF MEDICAL RESEARCH.

16 (C) A PERSON WHO VIOLATES THIS SECTION IS GUILTY OF A MISDEMEANOR
17 AND ON CONVICTION IS SUBJECT TO IMPRISONMENT NOT EXCEEDING 3 YEARS OR A
18 FINE NOT EXCEEDING \$50,000 OR BOTH.

19 20-1112.

20 (A) A PERSON MAY NOT CONDUCT OR ATTEMPT TO CONDUCT HUMAN
21 CLONING.

22 (B) A PERSON WHO VIOLATES THIS SECTION IS GUILTY OF A FELONY AND ON
23 CONVICTION IS SUBJECT TO IMPRISONMENT NOT EXCEEDING 10 YEARS OR A FINE
24 NOT EXCEEDING \$200,000 OR BOTH.

25 SECTION 2. AND BE IT FURTHER ENACTED, That the terms of the members
26 of the Stem Cell Research Commission appointed by the Governor shall expire as
27 follows:

28 (1) three in 2008;

29 (2) three in 2009; and

30 (3) two in 2010.

31 SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect
32 October 1, 2006.